Insulin Resistance

Insulin resistance correlated with Parkinson’s symptoms: One of the most ground breaking research discoveries of the past decade ….

Are you tired all the time. Do you usually have little energy?

The breakdown of glucose synthesis may well be the reason. Metabolically, insulin receptors play a key role in the regulation of glucose homeostasis, Insulin signaling controls access to blood glucose in body cells.

Do you typically feel better in the morning before you have had something to eat? This is a clue that you may be susceptible to insulin resistance. Fasting over night means that is a 12 hour or more period you have not eaten anything. This is the condition needed by the body for the liver to manufacture ketones. Before eating anything in the morning. your brain is being efficiently fueled by ketones rather than glucose which is the by product of eating anything.

Epidemiological evidence and experimental data support the interaction between Parkinson’s and diabetes. Treatments for diabetes show promising neuro-protective results in PD patients for both diabetic and non-diabetic patients, Therefore, the role of anti-diabetic treatments for Parkinson’s patients offers a promising therapeutic approach

Ask your self – why are so many persons diagnosed with neurological conditions so thin? A logical reason is that when they eat, their symptoms worsen, so they do not eat regularly

Studies that find the connection between insulin resistance and Parkinson’s symptoms

Mov Disord. 2022 Aug;37(8):1612-1623. The Impact of Type 2 Diabetes in Parkinson’s Disease. Dilan Athauda, James Evans, Anna Wernick, Gurvir Virdi, Minee L Choi, Michael Lawton, Nirosen Vijiaratnam, Christine Girges, Yoav Ben-Shlomo, Khalida Ismail, Huw Morris, Donald Grosset, Thomas Foltynie, Sonia Gandhi 

Abstract

Background: Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson’s disease (PD), but its effect on disease progression is not well understood.

Objective: The aim of this study was to investigate the influence of T2DM on aspects of disease progression in PD.

Methods: We analyzed data from the Tracking Parkinson’s study to examine the effects of comorbid T2DM on PD progression and quality of life by comparing symptom severity scores assessing a range of motor and nonmotor symptoms.

Results: We identified 167 (8.7%) patients with PD and T2DM (PD + T2DM) and 1763 (91.3%) patients with PD without T2DM (PD). After controlling for confounders, patients with Type 2 Diabetes had more severe motor symptoms, as assessed by Movement Disorder Society Unified Parkinson’s Disease Rating Scale, Part III (25.8 [0.9] vs. 22.5 [0.3] P = 0.002), and nonmotor symptoms, as assessed by Non-Motor Symptoms Scale total (38.4 [2.5] vs. 31.8 [0.7] P < 0.001), and were significantly more likely to report loss of independence (odds ratio, 2.08; 95% confidence interval [CI]: 1.34-3.25; P = 0.001) and depression (odds ratio, 1.62; CI: 1.10-2.39; P = 0.015). Furthermore, over time, patients with T2DM had significantly faster motor symptom progression (P = 0.012), developed worse mood symptoms (P = 0.041), and were more likely to develop substantial gait impairment (hazard ratio, 1.55; CI: 1.07-2.23; P = 0.020) and mild cognitive impairment (hazard ratio, 1.7; CI: 1.24-2.51; P = 0.002) compared with the PD group. 

Conclusions: In the largest study to date, T2DM is associated with faster disease progression in Parkinson’s, highlighting an interaction between these two diseases. Because it is a potentially modifiable metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for alleviating parkinsonian symptoms and slowing progression to disability and dementia. 

Mov Disord. 2021 Jun;36(6):1420-1429. Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression. Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce 

Abstract

Background: Type 2 diabetes (T2DM) and Parkinson’s disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. 

Objective: The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.

Methods: A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.

Results: In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.

Conclusions: Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression.   

J Parkinsons Dis. 2020;10(3):775-789. The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease. Julia L Y Cheong, Eduardo de Pablo-Fernandez, Thomas Foltynie Alastair J Noyce

Abstract

In recent years, an emerging body of evidence has forged links between Parkinson’s disease (PD) and type 2 diabetes mellitus (T2DM). In observational studies, those with T2DM appear to be at increased risk of developing PD, as well as experiencing faster progression and a more severe phenotype of PD, with the effects being potentially mediated by several common cellular pathways. The insulin signalling pathway, for example, may be responsible for neurodegeneration via insulin dysregulation, aggregation of amyloids, neuroinflammation, mitochondrial dysfunction and altered synaptic plasticity. In light of these potential shared disease mechanisms, clinical trials are now investigating the use of established diabetes drugs targeting insulin resistance in the management of PD.  

Robert

The Truth About Hydration

Everyone knows that without water we die. We also all know that a dehydrated body has no chance of clearing toxins or sustaining life.
How many of us realize we are dehydrated? I seem never to realize I need to drink water. I have heard from many members of my audience who report that they drink a lot of water so they could certainly not be dehydrated.
But guess what? Dehydration may be a primary reason for their symptoms.

Take a few minutes today to hear my interview with Jaroslav Boublik, an international expert on dehydration. His answers to my questions will likely surprise you.
Robert

What Distinguishes People Who Celebrate Successful Recoveries from Those Who Do Not

I personally find the argument Stephen Fowkes puts forth in this clip of my interview with him compelling. Many persons I have interviewed over the years are literally stuck “in the mud”, attempting to decide which therapies offer the promise of relief but unable to decide which one to pursue. One option after another are offered, but none seem plausible enough to act on.

Does this by any chance describe you? It does most people. The one criticism of Parkinsons Recovery has been that people become overwhelmed by the many viable choices are tendered that offer the promise of symptom relief. There are too many choices to filter through, so no action is taken.

Stephen makes a compelling argument that the people who have successful recoveries are those that take action on something. He even goes so far as to say it does not really matter what options are embraced. The secret to recovery is to take full control over your recovery program. So Stephen simply recommends that you act, do not hesitate. Take the steps your intuition informs are right for you in the moment. In doing so, you will celebrate symptom relief down the line and lead a full, productive long life.

 

Solutions for Memory Challenges and Thinking Difficulties

Are you struggling with short term or long term memory? I have formulated powerful solutions to these challenges many persons with Parkinson’s symptoms confront.

The number of new and innovative therapies that improve memory and thinking has skyrocketed these past few years. Many of them you have likely never even heard about because they are so new.

There is no doubt about it. Recent research revelations are transforming how memory issues associated with Alzheimer’s can be successfully treated.

I warmly invite you to enroll in my new online course, Road to Recovery from Alzheimers. If you are confronting memory challenges, the classes posted in my new online course offer the opportunity to sharpen memory and support clear thinking.

The classes are for everyone confronting mental difficulties – not just persons with a formal diagnosis of Alzheimers.

Innovative approaches, natural therapies and dietary recommendations are all presented that nurture memory and support clear thinking. All recommendations are grounded in evidence based research findings.

Click on the link to enroll.  You have the rare opportunity to choose the course tuition you wish to pay

https://www.parkinsonsrecovery.org/offers/S6LeCHqL

Robert Rodgers PhD

X – Plus 3: New Photobiomodulation Device from Vielight

Is a problematic symptom for you involve mobility challenges? Has rock solid walking become difficult? The new Vielight X – Plus 3 device may offer the support you need to transform wobbly walking to rock solid.

The Vielight X-Plus 3 device has four components: A head module, a body module and the nasal applicator. The information below was obtained from the Vielight.com website.

Head Module

The Head Module stimulates the cerebellum. Although the cerebellum accounts for approximately 10% of the brain’s volume, it has approximately  50% of all neurons in the brain.

The cerebellum is involved in the following functions:

Maintenance of balance and posture. The cerebellum is responsible for making postural adjustments to maintain balance. It modulates commands to motor neurons to compensate for shifts in body position or changes in load upon muscles.

Coordination of voluntary movements. Most movements are composed of different muscle groups acting together in a temporally coordinated fashion. One major function of the cerebellum is to coordinate the timing and force of these different muscle groups to produce fluid limb or body movements.

Motor learning. The cerebellum is important for motor learning. The cerebellum plays a major role in adapting and fine-tuning motor programs to make accurate movements through a trial-and-error process.

Body Module

Featured in a Vielight  COVID-19 study, the body module can be used to stimulate the thymus gland to aid immune function and response. It can also be positioned over joints and certain body parts, such as the shoulder or knees, to provide anti-inflammatory relief.

Intranasal Applicator

The Intranasal Applicator is designed to improve oxygenation which  leads to increased adenosine triphosphate (ATP) levels in various tissues.

Light energy absorbed by blood through the intranasal applicator  leads to an increase in nitric oxide release.

Nitric oxide is one of the most important factors affecting microcirculation. This leads to increases in vasodilation which contributes to improved oxygen delivery to tissues.

Summary

I have no hesitation in recommending the X-Plus 3 Vielight device to be considered to address mobility challenges in particular. The company is so confident in their devices that they encourage users to use their devices for up to 6 months. If you do not receive the benefit you need, return the used device Vielight for a 80% refund.

The company also offers a 10% discount to members of the Parkinsons Recovery community. Coupon code is healing4me if you order on line. if you call to order, just claim your 10% discount by indicating you were referred by Parkinsons Recovery. The Vielight order page link is below:

X-Plus 3 (Brain Systemic)

Diabetes and Parkinson’s

The most important research discovery of the decade … There is a significant connection between diabetes and Parkinson’s

Are you tired all the time. Do you usually have little energy?

The breakdown of glucose synthesis may well be the reason. Metabolically, insulin receptors play a key role in the regulation of glucose homeostasis, Insulin signaling controls access to blood glucose in body cells.

Do you typically feel better in the morning before you have had something to eat? This is a clue that you may be susceptible to insulin resistance. Fasting over night means that is a 12 hour or more period you have not eaten anything. This is the condition needed by the body for the liver to manufacture ketones. Before eating anything in the morning. your brain is being efficiently fueled by ketones rather than glucose which is the by product of eating anything.

Epidemiological evidence and experimental data support the interaction between Parkinson’s and diabetes. Treatments for diabetes show promising neuro-protective results in PD patients for both diabetic and non-diabetic patients. Therefore, the role of anti-diabetic treatments for Parkinson’s patients offers a promising therapeutic approach.

Ask your self – why are so many persons diagnosed with neurological conditions so thin? A logical reason is that when they eat, their symptoms worsen, so they do not eat regularly

Studies that find the connection between diabetes and Parkinson’s

Mov Disord. 2022 Aug;37(8):1612-1623. The Impact of Type 2 Diabetes in Parkinson’s Disease. Dilan Athauda, James Evans, Anna Wernick, Gurvir Virdi, Minee L Choi, Michael Lawton, Nirosen Vijiaratnam, Christine Girges, Yoav Ben-Shlomo, Khalida Ismail, Huw Morris, Donald Grosset, Thomas Foltynie, Sonia Gandhi 

Abstract

Background: Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson’s disease (PD), but its effect on disease progression is not well understood.

Objective: The aim of this study was to investigate the influence of T2DM on aspects of disease progression in PD.

Methods: We analyzed data from the Tracking Parkinson’s study to examine the effects of comorbid T2DM on PD progression and quality of life by comparing symptom severity scores assessing a range of motor and nonmotor symptoms.

Results: We identified 167 (8.7%) patients with PD and T2DM (PD + T2DM) and 1763 (91.3%) patients with PD without T2DM (PD). After controlling for confounders, patients with Type 2 Diabetes had more severe motor symptoms, as assessed by Movement Disorder Society Unified Parkinson’s Disease Rating Scale, Part III (25.8 [0.9] vs. 22.5 [0.3] P = 0.002), and nonmotor symptoms, as assessed by Non-Motor Symptoms Scale total (38.4 [2.5] vs. 31.8 [0.7] P < 0.001), and were significantly more likely to report loss of independence (odds ratio, 2.08; 95% confidence interval [CI]: 1.34-3.25; P = 0.001) and depression (odds ratio, 1.62; CI: 1.10-2.39; P = 0.015). Furthermore, over time, patients with T2DM had significantly faster motor symptom progression (P = 0.012), developed worse mood symptoms (P = 0.041), and were more likely to develop substantial gait impairment (hazard ratio, 1.55; CI: 1.07-2.23; P = 0.020) and mild cognitive impairment (hazard ratio, 1.7; CI: 1.24-2.51; P = 0.002) compared with the PD group. 

Conclusions: In the largest study to date, T2DM is associated with faster disease progression in Parkinson’s, highlighting an interaction between these two diseases. Because it is a potentially modifiable metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for alleviating parkinsonian symptoms and slowing progression to disability and dementia. 

Mov Disord. 2021 Jun;36(6):1420-1429. Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression. Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce 

Abstract

Background: Type 2 diabetes (T2DM) and Parkinson’s disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. 

Objective: The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.

Methods: A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.

Results: In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.

Conclusions: Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression.

CBD Therapy for Parkinson’s

My research efforts identify recently invented or formulated products that show promise in helping to reverse symptoms of Parkinson’s disease. The CBD Therapy previewed in this post is just that – a new formulation that I think is worth seriously considering. It is called 10xPure Gold Super 1500 CBDa oil.

This formulation is a significant improvement over traditional CBD oils. It has been formulated to have 10 times the penetration and potency of other CBD products. This means you should be able to take fewer drops and spend less to celebrate symptom relief.

Once you purchase from CTFO as I have, you become an “affiliate” of the company. It is a direct sales company – not a MLM.

CTFO conducts laboratory testing on all of their samples to insure that the contents are organic and the concentrations match what is advertised. All laboratory testing is available for inspection. If a CBDa bottle is advertised to contain 450 mg of CBAa , you can be assured it does. When they advertise it is organic, you can rest assured it is.

I have no hesitation recommending this company. They generously extend a 100% money back guarantee if the product does not offer the symptom relief you seek. You only need to return the empty bottle within 60 days and your purchase price will be refunded.

There is no risk in trying this therapy out to see if it offers relief from your symptoms.

Watch the videos about 10X Pure Gold 1500 CBDa on the CTFO website by clicking on the secure link below:

https://parkinsonsrecovery.myctfo.com/product_details.html?productcode=super1500

I recommend this option because it offers the greatest concentration of CBD (450 mg) at the best price per mg. This means you will benefit from needing to take less to celebrate symptom relief.

Check out the research on CBD oil and Parkinson’s. You will be impressed with the number of studies reporting positive outcomes for symptoms of Parklnson’s disease alone.

What is CBD Oil?

CBD stands for “cannabinoid oil”. It is extracted from either the Hemp plant or Marijuana. CBD allows for the benefits of medical marijuana without the high that is associated with THC. As such, CBD in itself has no psychedelic properties and is generally considered safe for consumption. It is legal in the United States and many other countries as well.

CBD Side Effects

Studies of cannabidiol (CBD) report it is well-tolerated but may cause tiredness, diarrhea or change appetites.

Have You Already Tried CBD But Were Disappointed with the Outcome?

Know that no therapy – including CBD – will necessarily offer relief from your symptoms. Everyone has a unique body with a unique set of needs.

I have drawn the conclusion, however, that more people experience relief from their symptoms taking CBD than do not. In light of the now extensive research evidence, I have no hesitation in recommending CBD as a viable option.

There are two reasons why you might have not experienced the outcomes expected from taking CBD oil.

  • A first explanation for why some people do not experience symptom relief is that the concentration of CBD oil they took was insufficient. Research using patients diagnosed with Parkinson’s disease find that subjects who took a minimum of 300 mg showed improvement. Subjects treated with 75 mg showed no improvement.
  • A second possible explanation is that the concentration of CBD taken was less than the concentration advertised. Because there are millions of dollars to be made selling CBD which is now legal,  many overnight companies have surfaced. Some are legitimate. Others are not. A CBD product can be listed as having a 100 mg concentration of CBD (which is a low concentration) but the actual bottle contains only 25 mg or less. As a promising new health discovery, many fly by night companies have seized the opportunity to make a quick profit by selling a product that contains little of what is advertised.

Which CTFO Products Should You Try?

CTFO continues to formulate new products that all contain their patented form of cannabinoid oil. Among the many options available I recommend that you consider getting the 10X 1500 Pure Full Spectrum CBDa oil drops. Below is the description that I copied from the CTFO website. The highest dosage (450 mg) offers the best value.

“This supercharged Full Spectrum CBD oil is hydrophilic, making it easily absorbed into the body. It provides accelerated, increased absorption and potency and acts as an anti-bacterial and prebiotic. CBD has been known to support healthy blood sugar levels, promote healthy energy levels, relieve anxiety, aid in digestion, support optimal immune function and the regeneration of healthy cells, and promote a sense of serenity and overall well-being.”

Visit the page below to watch videos about CBDa and the 10xPure Gold CBD product:
https://parkinsonsrecovery.myctfo.com/product_details.html?productcode=super1500

Jump Start to Recovery Crash Course

There exists a wide variety of factors that can inflame Parkinson’s symptoms.  Of course, everyone knows dopamine is often deficient, but what is the cause of this? The most important reason that symptoms flare up is unrelenting anxiety caused by stress.

Members of my global audience consistently say they had to deal with extremely stressful situations  before their symptoms became problematic. Reports vary but always involve challenges in their life that result in high anxiety and stress.

  • Perhaps their business confronted financial or legal problems.
  • Perhaps a family member died.
  • Perhaps a child became addicted to alcohol or street drugs.
  • Perhaps there was a stressful divorce.

Regardless of the specifics, anxiety persists day in and day out, week after week.  The stressful circumstances do not let up. Relaxation is not an option. Worry is constant. The neurological system becomes locked on overdrive.

Feelings triggered by the continuous onslaught of stressful circumstances get stuck in the body like super glue. To celebrate a relief of symptoms, any and all trauma that has been  trapped in the cellular structure of the body has to be released.

  • Is your body rigid?
  • Are you often anxious?
  • Is stress unrelenting?

The best way to calm and even eliminate symptoms  is to address and release traumas from the past including childhood. In doing so the body  becomes flexible, calmer and less stressed.

I have developed a free course which offers ways to release the traumas that are trapped in your physical body. Click on the link below to register:

Jump Start to Recovery Crash Course  

Robert

Parkinsons Recovery Support Group Forum

I have created a new way for you to connect with one another 24/7. Up until now – the only opportunity to connect has been the last Sunday of the month. Now – you can connect with me and others every day. I plan on connecting into the forum around noon (pacific time) on weekdays.

Parkinsons Recovery Support Group Forum

If you are already enrolled in any of my classes on Kajabi – you already have instant access to the Forum. You will see it listed on your course page.

You may need to register with Kajabi which involves providing your email and setting a password. Access to the forum is free. Here is the link to do so:

https://www.parkinsonsrecovery.org/offers/2mdKUTp5

Since this is new – there may be no one on the forum when you connect. This will change as more people learn about it!

Robert

Is Parkinson’s Disease Degenerative?

Many people hold the belief that Parkinsons disease is degenerative. With this expectation, a person is destined to be worse off year after year. Is Parkinsons disease degenerative? That is clearly what most people diagnosed with Parkinson’s believe.

Every  holiday season, Parkinsons Recovery sponsors a survey to determine whether or not persons diagnosed with Parkinsons do in fact continue to deteriorate year after year. The 2022 survey asked respondents to answer the question:

“Since the holiday season one year ago, have you been generally feeling better, the same or worse?”

If it is in fact true that Parkinsons disease is “degenerative,” 100% of individuals responding to the 2022 survey will report they were worse off. No one would report they were better. No one would report they were the same.

In stark contrast to the expectation that Parkinsons disease is “degenerative”,  seventy two percent (72%)  of persons who answered this question reported they were either feeling better or the same.  Of the 72% of respondents who reported they were either feeling the same or better, thirty-one percent (32%) reported that they were better.

Previous Parkinsons Recovery surveys found 65% of respondents has been feeling either better or the same.  When we cumulate results from previous years, we find the following:

Cumulative Results: All Survey Years

HAVE YOU BEEN FEELING: NUMBER OF ANSWERS PERCENT
1027 100%
BETTER 247 24%
ABOUT THE SAME 422 41%
WORSE 358 35%

Results for the most recent survey show a modest increase in the number of persons reporting they were doing better when considering results for all years (i.e.: 32% versus 24%).

You might well believe that when a person reports they are the “same” it always means they continued to struggle with the same troublesome symptoms over the previous year and thus did not report feeling better or worse. This is certainly the experience for some respondents.

Other respondents who reported they were “doing the same” over the previous year were actually doing quite well overall (not poorly).  When a respondent reports “about the same” it does not mean necessarily that their symptoms are problematic.

We also know that none of us are accurate trackers of our personal health. When ask about our health it is not uncommon for any of us to report we have been about the same over the previous year when in reality our health improved. For this reason our results are conservative estimates.

Summary

While a majority of persons diagnosed with Parkinson’s disease hold he belief that their condition is degenerative, these survey results clearly indicate this false belief is misguided. Yes – some people do “deteriorate”. Our results estimate approximately one-third of persons we surveyed fall into this category. The vast majority of the individuals who responded to the Parkinsons Recovery annual survey report they were either doing better or the same.

Is it really possible to recovery from a diagnosis of Parkinson’s? Results of the Parkinsons Recovery show the answer is yes.

Robert